A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumoursA phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours, Published online: 14 November 2018; doi:10.1038/s41416-018-0322-4A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

Source: British Journal of Cancer - November 14, 2018 Category: Cancer & Oncology Authors: Alison M. Schram Leena Gandhi Monica M. Mita Lars Damstrup Frank Campana Manuel Hidalgo Enrique Grande David M. Hyman Rebecca S. Heist Source Type: research